GeoVax Secures Patent for Innovative Malaria Vaccine Design
TL;DR
GeoVax Labs secures a patent for a multi-antigenic vaccine design, offering a competitive edge in combating malaria and other infectious diseases with enhanced immune responses.
The patent covers a vaccine using GeoVax’s MVA viral vector to express Plasmodium falciparum proteins, forming VLPs that boost vaccine potency and immune responses.
This innovative vaccine technology by GeoVax aims to reduce malaria's global toll, particularly in sub-Saharan Africa, marking a step forward in global health security.
GeoVax's new patent introduces a vaccine that assembles virus-like particles in vivo, a breakthrough in fighting malaria and potentially other infectious diseases.
Found this article helpful?
Share it with your network and spread the knowledge!
GeoVax Labs, Inc., a biotechnology firm specializing in vaccine development, has announced the issuance of a U.S. patent for a groundbreaking vaccine construct designed to prevent malaria. The patent, U.S. Patent No. 12,329,808, covers a recombinant Modified Vaccinia Ankara (MVA) viral vector that expresses immunogenic proteins from Plasmodium falciparum, the parasite responsible for malaria. This innovative approach utilizes virus-like particles (VLPs) to enhance vaccine potency, aiming to induce both humoral and T-cell responses.
David Dodd, President and CEO of GeoVax, emphasized the importance of this patent in advancing vaccines for high-consequence pathogens, highlighting the company's commitment to global health security. With malaria causing over 600,000 deaths annually, primarily in sub-Saharan Africa, this development represents a critical step forward in combating the disease.
GeoVax's portfolio now includes over 135 granted or pending patent applications across various fields, including oncology and infectious diseases. This latest patent underscores the company's strategic focus on addressing both endemic and emerging health threats through its multi-antigenic platform strategy.
Curated from NewMediaWire
